John P Byrnes

US Patent:

20050171139, Aug 4, 2005

Filed:

Oct 7, 2004

Appl. No.:

10/961101

Inventors:

Ronald Hammer - Cohasset MA, US
John Byrnes - Ashland MA, US

International Classification:

A61K031/4745
A61K031/40

US Classification:

514295000, 514424000

Abstract:

The invention provides compositions and methods for treating a human diagnosed as having, or at risk for developing, a psychotic symptom by administering a full agonist of a dopamine D2-like receptor to the human. The agonist can be known or identified by screening methods described herein.

US Patent:

20100137403, Jun 3, 2010

Filed:

Jul 9, 2009

Appl. No.:

12/499910

Inventors:

Scott Malstrom - Reading MA, US
John J. Byrnes - Ashland MA, US
Michelle Wolfe - Tyngsboro MA, US

International Classification:

A61K 31/385
A61P 25/00

US Classification:

514436

Abstract:

A method for enhancing cognition or inhibiting cognitive decline in a subject comprises selecting a Ca channel blocker that is effective, when administered intravenously to an animal in a nontoxic amount, to increase NF-κB expression in the brain of the animal; and administering the selected Ca channel blocker to the subject, via a systemic route that affords an adequate therapeutic window for cognition-enhancing or cognitive decline-inhibiting effectiveness of the selected Ca channel blocker, in an amount within the therapeutic window. The selected Ca channel blocker can be, for example, tiapamil or a pharmaceutically acceptable salt or prodrug thereof.

US Patent:

20100204286, Aug 12, 2010

Filed:

Feb 11, 2010

Appl. No.:

12/704286

Inventors:

Stephen R. Donahue - Lexington MA, US
John J. Byrnes - Ashland MA, US

International Classification:

A61K 31/426
A61K 31/4172
A61K 31/415
A61P 35/00
A61P 1/00

US Classification:

514365, 514400, 514406

Abstract:

A method for moderating a gastrointestinal adverse effect induced by at least one cytotoxic agent, for example ionizing radiation and/or at least one chemotherapeutic agent, in a subject comprises administering to the subject a therapeutically effective amount of an ACE2 inhibitor or a compound selected from (S,S)-2-[1-carboxy-2-[3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl]-ethylaminol-4-methylpentanoic acid (ORE1001), pharmaceutically acceptable salts thereof and prodrugs thereof. A method for treating a cancerous condition in a subject comprises administering to the subject (a) at least one cytotoxic anticancer agent, for example ionizing radiation and/or at least one chemotherapeutic agent; and (b) an ACE2 inhibitor or a compound selected from ORE1001, pharmaceutically acceptable salts thereof and prodrugs thereof in an amount effective to moderate a gastrointestinal adverse effect induced by the anticancer agent.